Baird Financial Group Inc. Cuts Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Baird Financial Group Inc. decreased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 6.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 46,025 shares of the medical equipment provider’s stock after selling 3,026 shares during the quarter. Baird Financial Group Inc.’s holdings in Zimmer Biomet were worth $4,862,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of ZBH. CKW Financial Group boosted its stake in shares of Zimmer Biomet by 11.7% in the 4th quarter. CKW Financial Group now owns 955 shares of the medical equipment provider’s stock valued at $101,000 after purchasing an additional 100 shares in the last quarter. Romano Brothers AND Company boosted its position in Zimmer Biomet by 1.1% during the fourth quarter. Romano Brothers AND Company now owns 9,466 shares of the medical equipment provider’s stock valued at $1,000,000 after buying an additional 102 shares during the period. Dorsey & Whitney Trust CO LLC grew its stake in shares of Zimmer Biomet by 2.3% during the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 4,594 shares of the medical equipment provider’s stock valued at $485,000 after buying an additional 102 shares during the last quarter. M&T Bank Corp increased its holdings in shares of Zimmer Biomet by 0.4% in the fourth quarter. M&T Bank Corp now owns 26,827 shares of the medical equipment provider’s stock worth $2,834,000 after buying an additional 108 shares during the period. Finally, MGO One Seven LLC boosted its holdings in Zimmer Biomet by 5.1% during the 4th quarter. MGO One Seven LLC now owns 2,254 shares of the medical equipment provider’s stock valued at $238,000 after acquiring an additional 110 shares during the period. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Up 0.1 %

Shares of NYSE:ZBH opened at $95.22 on Friday. Zimmer Biomet Holdings, Inc. has a 12-month low of $89.92 and a 12-month high of $122.25. The stock has a market capitalization of $18.84 billion, a price-to-earnings ratio of 21.40, a PEG ratio of 1.95 and a beta of 0.78. The stock has a fifty day simple moving average of $104.43 and a two-hundred day simple moving average of $106.11. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.77 by $0.04. The company had revenue of $1.91 billion for the quarter, compared to analysts’ expectations of $1.89 billion. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. Zimmer Biomet’s revenue was up 1.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.94 EPS. On average, research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, April 30th. Investors of record on Monday, March 31st were given a $0.24 dividend. The ex-dividend date was Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 1.01%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.24%.

Analysts Set New Price Targets

ZBH has been the subject of a number of analyst reports. BTIG Research reissued a “buy” rating on shares of Zimmer Biomet in a research note on Monday, April 14th. JMP Securities cut their price target on shares of Zimmer Biomet from $140.00 to $125.00 and set a “market outperform” rating on the stock in a report on Wednesday. Truist Financial set a $101.00 price objective on shares of Zimmer Biomet in a research note on Tuesday. Barclays cut their target price on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research note on Monday, February 10th. Finally, Wells Fargo & Company dropped their price objective on Zimmer Biomet from $113.00 to $98.00 and set an “equal weight” rating for the company in a report on Tuesday. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus price target of $114.15.

Insider Buying and Selling at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of the company’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the sale, the senior vice president now owns 8,768 shares in the company, valued at approximately $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.39% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.